Damora Therapeutics (DMRA) Live Share Price, Invest From India

Damora Therapeutics Stock Performance

as on November 11, 2026 at 7:24 am IST

Day's Low
Day's High
$23.45
Day's Price Range
$24.55
$23.91
1.92%
Downside
2.68%
Upside
52 Week's Low
52 Week's High
52-Week Price Range
$23.91
100.00%
Downside
-100.00%
Upside

Damora Therapeutics share price movements today

Previous Close: $24.07
Open: $23.75
Volume: 455.5K
Market Cap: $1.5B
Day's Low - High: $23.45 - $24.55

Damora Therapeutics Historical Returns

1 Month Return: + 14.18 %
3 Month Return: -18.52 %
1 Year Return: 0 %
3 Year Return: 0 %
5 Year Return: 0 %

Damora Therapeutics Stock Fundamentals & Key Indicators

Check Damora Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.5B

EPS (TTM)

-122.82

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.19

Industry PE ratio

-7.60

PEG Ratio

0.00

EBITDA

-299.9M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-66.20%

Damora Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Damora Therapeutics with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Damora Therapeutics	StrongBuy	$1.5B	NA	-0.19	0.00%	0.00%
Moderna	Neutral	$101.5B	17.49%	-35.95	28.00%	0.00%
BeOne Medicines	StrongBuy	$46.5B	NA	66.55	88.39%	0.00%
Vertex Pharmaceuticals	StrongBuy	$138.7B	193.16%	34.94	85.57%	0.00%
Regeneron	Buy	$93.5B	47.86%	19.26	85.77%	0.41%

Analyst Recommendation on Damora Therapeutics Stock

Based on 8 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 8 analysts, 100% of analysts recommend a 'BUY' rating for Damora Therapeutics. Average target price of $47.1428571428571

Damora Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Damora Therapeutics.

Current Price

$23.91

Analyzed by

8 Analysts

High

$59

Low

$40

Damora Therapeutics target price $0, a slight upside of 0% compared to current price of $23.91. According to 8 analysts rating.

Indian Investors' Interest in Damora Therapeutics Stock

Search interest for Damora Therapeutics Stock has decreased by -49% in the last 30 days, reflecting a downward trend in search activity.

Time period: October 12, 2026 to November 11, 2026

Change:-49% versus previous 30 day period

Damora Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	-	0	0	-
Operating Income	-13	-11	-5	-5	-5	-4	-201	-30	-34	-36
EBITDA	-12	-10	-7	-6	-5	-5	-200	-27	-34	-36
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-12	-10	-8	-6	-5	-5	-200	-27	-30	-31
Income Tax Expense	-	-	-	-	-	0	0	0	0	-
Net Income	-12	-10	-8	-6	-5	-5	-200	-27	-31	-31
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Damora Therapeutics Annual Profit & Loss

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	-	-	-
Gross Profit	-	0	0	0	0	0	0	-
Operating Income	-12	-38	-33	-52	-61	-36	-16	-210
EBITDA	-12	-38	-33	-51	-61	-37	-21	-209
Interest Expense	2	-	-	-	-	-	-	-
Depreciation	-	0	0	0	0	0	0	0
Income Before Tax	-15	-36	-34	-51	-61	-38	-21	-209
Income Tax Expense	-	-	-	-	-	-	0	0
Net Income	-15	-36	-34	-51	-61	-38	-21	-209
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Damora Therapeutics Quarterly Cash Flow

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Net Income	-12	-10	-8	-6	-5	-5	-200	-27	-31	-31
Operating Cash Flow	-9	-7	-8	-11	-5	-4	0	-20	-21	-17
Investing Cash Flow	1	3	8	9	5	6	-17	-	-	-178
Financing Cash Flow	0	2	0	-	-	-	266	295	29	5
Change in Cash	-7	-2	0	-1	0	1	250	275	7	-190

Damora Therapeutics Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-15	-36	-34	-51	-61	-38	-21	-209
Operating Cash Flow	-13	-19	-38	-52	-42	-36	-18	-6
Investing Cash Flow	-	0	-	-48	12	22	11	-17
Financing Cash Flow	42	-	187	-	0	2	-	266
Change in Cash	30	-19	152	-101	-29	-11	-7	243

Global Institutional Holdings in Damora Therapeutics

Check out the Institutions with significant holdings in Damora Therapeutics.

Funds	Holdings
Fairmount Funds Management LLC	14.07%
Peter Harwin	14.07%
BlackRock, Inc.	5.11%
Fidelity Mt. Vernon Street Trust	4.57%
Peter Kolchinsky	3.88%

See all

Insights on Damora Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, DMRA stock has moved up by 9.0%
NO EFFECT
Against Peers
In the last 3 years, Moderna, Inc. Common Stock has given 284.0% return, outperforming this stock by 218.0%
NO EFFECT
Against Peers
In the last 1 year, Moderna, Inc. Common Stock has given 986.4% return, outperforming this stock by 946.9%

About Damora Therapeutics

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Organisation	Damora Therapeutics
Headquarters	Building 23, Waltham, MA, 02453, US
Industry	Biotechnology
CEO	Jennifer A. Jarrett

Key Management of Damora Therapeutics

Name	Title
Mr. Brian Burkavage CPA	Senior VP of Finance, Principal Financial & Accounting Officer
Mr. Sherwin Sattarzadeh	Chief Operating Officer
Dr. Becker Hewes M.D.	Chief Medical Officer
Mr. Garrett Winslow Esq.	Senior VP, General Counsel & Corporate Secretary
Ms. Jennifer A. Jarrett M.B.A.	CEO, President & Director
Mr. Ulf J. Nilsson Ph.D.	Co-Founder
Dr. Hakon Leffler M.D., Ph.D.	Co-Founder
Prof. Tariq Sethi B.Sc., FRCP, M.A., M.D., Ph.D.	Co-Founder

FAQs

What is Damora Therapeutics share price today?

Damora Therapeutics share price today is $23.91 as on November 11, 2026 at 1:54 am IST. Damora Therapeutics share today touched a day high of $24.55 and a low of $23.45.

What is the 52 week high and 52 week low for Damora Therapeutics share?

Damora Therapeutics share touched a 52 week high of $0.00 on January 1, 1970 and a 52 week low of $0.00 on January 1, 1970. Damora Therapeutics stock price today i.e. November 11, 2026 at 1:54 am IST is trending at $23.91,which is -Infinity% down from its 52 week high and Infinity% up from its 52 week low.

What is Damora Therapeutics's market capitalisation today?

Damora Therapeutics market capitalisation is $0.00T as on November 11, 2026 at 1:54 am IST.

How to invest in Damora Therapeutics Stock (DMRA) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Damora Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Damora Therapeutics Stock (DMRA) from India?

Indian investors can start investing in Damora Therapeutics (DMRA) shares with as little as ₹93.917999267578 or $1 (as of November 11, 2026 at 1:54 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹939.18 in Damora Therapeutics stock (as per the Rupee-Dollar exchange rate as on November 11, 2026 at 1:54 am IST). Based on Damora Therapeutics share’s latest price of $23.91 as on November 11, 2026 at 1:54 am IST, you will get 0.4182 shares of Damora Therapeutics. Learn more about fractional shares .